Browsing: Lecanemab

Log In or Register as a healthcare professional to read the full article.

A novel Alzheimer’s disease treatment drug, lecanemab, developed by Japanese pharmaceutical company Eisai and US firm Biogen, is nearing full approval in the US. Excitement is also building in Japan where the population of Alzheimer’s patients is growing and Prime Minister Fumio Kishida has prioritised dementia. The drug is undergoing an expedited review by the Japanese Pharmaceuticals and Medical Devices Agency and could potentially be approved this autumn.

Lecanemab is one of the first experimental drugs for dementia which appears to help in slowing down the progression of cognitive decline.